Article · Wikipedia archive · Last revised Jul 24, 2026

Cyheptamide

Cyheptamide was a investigational new drug that was developed by Ayerst Research Laboratories in the 1960s and was evaluated as an anticonvulsant.

Last revised
Jul 24, 2026
Read time
≈ 1 min
Length
198 w
Citations
4
Source
Wikipedia ↗
Cyheptamide
Clinical data
Other namesCyheptamine
Identifiers
  • tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.027.792
Chemical and physical data
FormulaC16H15NO
Molar mass237.302 g·mol−1
3D model (JSmol)
  • C1CC2=CC=CC=C2C(C3=CC=CC=C31)C(=O)N
  • InChI=1S/C16H15NO/c17-16(18)15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)15/h1-8,15H,9-10H2,(H2,17,18)
  • Key:APBVLLORZMAWKI-UHFFFAOYSA-N

Cyheptamide was a investigational new drug that was developed by Ayerst Research Laboratories in the 1960s and was evaluated as an anticonvulsant.1

Cyheptamide undergoes significant metabolic transformation in both animals and humans, primarily through hydroxylation pathways.2

Cyheptamide exhibits moderate acute toxicity in animal models, with species-specific variations in lethal dose values.3

SGB-017 has a similar chemical structure and has also been evaluated for its potential use as an anticonvulsant.4

Chemical structure of SGB-017 source ↗
See also

See also

References

References

  1. "Cyheptamide". Inxight: Drugs. NCATS. Retrieved 2025-06-25.
  2. Kraml M, Sestanj K, Dvornik D (September 1971). "Metabolism of the anticonvulsant 10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-carboxamide. I. Metabolic fate of (14C)cyheptamide in animals and man". Biochemical Pharmacology. 20 (9): 2327–2338. doi:10.1016/0006-2952(71)90232-2. PMID 5163146.
  3. van Eeken CJ, Birtwhistle RD, Mulder D (November 1970). "Toxicological study of cyheptamide: 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carboxamide (BS 7029)". Archives Internationales de Pharmacodynamie et de Therapie. 188 (1): 79–85. PMID 5485105.
  4. Lin, S. S., Sun, L. R. (December 1999). "SGB‐017 (ADCI): A Novel Anticonvulsant with a Dual Mechanism of Action". CNS Drug Reviews. 5 (4): 365–378. doi:10.1111/j.1527-3458.1999.tb00111.x.